Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways PLC is well-positioned for growth due to the anticipated Phase III clinical trial data expected in the latter half of the quarter, with potential share value doubling on positive outcomes and heightened visibility towards regulatory approval. The company has increased its probability of success to 75%, supported by strong Phase IIb results showing notable improvements in measured depression scales and a solid infrastructure for trial conduct and commercial rollout. Additionally, the expansion of treatment options and the strengthening intellectual property surrounding COMP360, combined with a favorable regulatory environment and growing patient enthusiasm, contribute to a robust outlook for Compass Pathways in the mental health therapeutic market.

Bears say

Compass Pathways PLC faces substantial risks that could adversely impact its stock performance, primarily tied to the clinical success of its proprietary psilocybin formulation, COMP360, particularly in upcoming Phase III trials. Should COMP360 fail to demonstrate clinically meaningful benefits, encounter safety concerns, or struggle with commercialization and regulatory approval, it could prompt significant downward adjustments in the company's valuation and stock price. Additionally, broader caution in the psychedelic sector, competitive pressures, and financial constraints related to ongoing R&D and SG&A expenditures further exacerbate the negative outlook for the company's financial trajectory.

COMPASS Pathways (CMPS) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 8 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.